The Ministry of Health of Welfare plans to soon announce an appropriate compensation plan for the innovative value of new drugs, including novel homegrown drugs. The health authorities’ plan is to deliberate its plan by the Health Insurance Policy Review Committee within the month and release the results to the public soon.

The domestic pharmaceutical industry is hoping that this measure will provide additional points to non-inferior new drugs.

Non-inferior new drugs contain new active ingredients and have proven to be non-inferior to existing drugs. Most new drugs developed in the domestic pharmaceutical industry fall into this category.

The novel homegrown drugs, No. 3